Table 2 Sensitivity analysis of objective response rate of azacitidine in MDS
From: Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
| Â | Objective Response Rate Random Effects Model | |
|---|---|---|
Pooled rate (%) | CI | |
All patients (N* = 7520) | ||
 7–0-0 (N = 5545) | 44.8 | (42.8, 45.5) |
 5–0-0 (N = 1207) | 41.2 | (39.2, 41.9) |
 5–2-2 (N = 768) | 45.8 | (42.6, 46.4) |
MDS patients only (N = 2966) | ||
 7–0-0 (N = 2187) | 45.9 | (44.1, 46.7) |
 5–0-0 (N = 536) | 39.9 | (36.8, 40.5) |
 5–2-2 (N = 243) | 50.6 | (48.7, 51.3) |
IPSS int-2/hi patients (N = 1180) | ||
 7–0-0 (N = 926) | 46.8 | (44.9, 47.3) |
 5–0-0 (N = 112) | 54.6 | (53.8, 55.0) |
 5–2-2 (N = 142) | 60.7 | (59.0, 61.5) |
Randomized Controlled Trials (N = 883) | ||
 7–0-0 (N = 440) | 43.5 | (43.0, 43.7) |
 5–0-0 (N = 320) | 38.0 | (35.4, 38.2) |
 5–2-2 (N = 123) | 48.2 | (48.0, 48.6) |
Prospective Observational Studies (N = 1131) | ||
 7–0-0 (N = 401) | 45.9 | (44.2, 46.9) |
 5–0-0 (N = 481) | 39.3 | (35.8, 40.1) |
 5–2-2 (N = 249) | 40.0 | (34.0, 40.5) |
Retrospective Observational Studies (N = 4930) | ||
 7–0-0 (N = 3910) | 46.8 | (44.4, 47.5) |
 5–0-0 (N = 624) | 46.2 | (44.9, 47.0) |
 5–2-2 (N = 396) | 49.8 | (47.5, 50.6) |